Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Selectins01:25

Selectins

3.3K
Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.3K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Molecular Targets
  11. Bispecific Antibody For Lung Cancer: Mechanisms And Clinical Insights

Bispecific antibody for lung cancer: mechanisms and clinical insights

Wei Chen1, Afang Zhou2, Yunfeng Zhou1

  • 1Department of Thoracic Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Frontiers in Immunology
|June 13, 2025

Related Experiment Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

8.9K

View abstract on PubMed

Summary
This summary is machine-generated.

Bispecific antibodies offer new hope for lung cancer patients, showing promise in clinical trials and approved treatments. This review explores their mechanisms, progress, and future potential in treating this refractory malignancy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Lung cancer remains a significant challenge with low five-year survival rates despite existing therapies.
  • Bispecific antibodies (bsAbs) are emerging as a promising therapeutic class due to their unique dual-binding capabilities.
  • Recent approvals and ongoing trials highlight the growing importance of bsAbs in lung cancer treatment.

Purpose of the Study:

  • To review the structure and mechanisms of action of bispecific antibodies for lung cancer.
  • To summarize the clinical progress of bispecific antibodies in lung cancer therapy.
  • To analyze the challenges and future directions for bispecific antibody applications in lung cancer.

Main Methods:

  • Literature review of bispecific antibodies in lung cancer treatment.
Keywords:
bispecific antibodiesimmunotherapylung cancernovel therapies

Related Experiment Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.2K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

8.6K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

8.9K
  • Analysis of approved bispecific antibody drugs.
  • Summary of ongoing clinical trials for bispecific antibodies in lung cancer.
  • Discussion of challenges and future prospects.

    • Main Results:

    • Three bispecific antibodies have been approved for lung cancer treatment.
    • Numerous bispecific antibodies are under clinical investigation for safety and efficacy.
    • Bispecific antibodies demonstrate novel functional mechanisms and therapeutic potential.

    Conclusions:

    • Bispecific antibodies represent a significant advancement in lung cancer therapy.
    • Further research and clinical trials are essential to optimize bsAbs application.
    • The future of lung cancer treatment is likely to involve expanded use of bispecific antibodies.
    targeted therapy